B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MGLL

MOLECULAR TARGET

monoglyceride lipase

UniProt: Q99685NCBI Gene: 113439 compounds

MGLL (monoglyceride lipase) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MGLL

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1urb 5974.0858
2tanshinone iia3.7441
3arachidonyl trifluoromethylketone2.7715
4methoxyarachidonoyl fluorophosphonate2.7715
5thiram2.4811
6bispiperidinylthiocarbonyldisulfide2.208
7bispyrrolidinylthiocarbonyldisulfide1.956
8biphenylboronic acid1.795
9kml291.393

About MGLL as a Drug Target

MGLL (monoglyceride lipase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented MGLL interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MGLL inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.